A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
Phase of Trial: Phase III
Latest Information Update: 20 Jan 2020
Price : $35 *
At a glance
- Drugs Risankizumab (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 15 May 2019 Planned End Date changed from 5 Dec 2024 to 3 Dec 2024.
- 12 Mar 2019 Planned End Date changed from 24 Oct 2024 to 5 Dec 2024.
- 12 Mar 2019 Status changed from not yet recruiting to recruiting.